Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine

DOI Web Site 参考文献10件 オープンアクセス
  • Kishikawa Hiroshi
    Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital
  • Nishida Jiro
    Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital
  • Inokuchi Sayaka
    Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital
  • Kaida Shogo
    Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital
  • Morishita Tetsuo
    Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital
  • Hibi Toshifumi
    Department of Internal Medicine, School of Medicine, Keio University

書誌事項

公開日
2008
DOI
  • 10.4993/acrt.16.21
公開者
日本癌病態治療研究会

この論文をさがす

説明

A 74-year-old male was admitted to our hospital in August 2006 because of an exacerbation of the symptom of diabetes mellitus. Abdominal CT showed locally advanced cancer of the head of the pancreas with encasement of the superior mesenteric artery, suggesting that the lesion was unresectable. The patient was scheduled for treatment with gemcitabine at the standard dose of 1000 mg/m2 once a week for 3 consecutive weeks followed by a one week rest, but on day 7 of cycle 1, grade 3 of hematological toxicity was diagnosed, and the schedule was changed to biweekly administration at a dose of 1000 mg/m2. The biweekly low-dose gemcitabine regimen slightly reduced tumor size, and the regimen was continued for 12 months. This case suggests that this new biweekly regimen of gemcitabine can be used as a safe and effective first-line chemotherapy for patients with advanced pancreatic cancer who are unable to tolerate the standard regimen of gemcitabine.

収録刊行物

参考文献 (10)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ